PharmaCorp to acquire Western Canada pharmacy for $2.4 million

SASKATOON - PharmaCorp Rx Inc. (TSXV:PCRX), a pharmaceutical retailer with a market capitalization of $1.1 billion and annual revenues of $703 million, has agreed to acquire a PharmaChoice Canada bannered pharmacy in Western Canada for $2.4 million, according to a press release statement issued Thursday.

The acquisition, formalized through a share purchase agreement dated June 24, 2025, will give PharmaCorp 100% interest in the pharmacy. The company plans to fund the purchase using cash on hand, supported by its strong liquidity position with a current ratio of 2.41 and moderate debt levels.

The transaction is expected to close around July 31, 2025, subject to customary closing conditions. The final purchase price may be adjusted based on the net asset value as of the closing date. No finder’s fee is payable for this acquisition.

"This transaction reflects the strength of our strategic alliance with PharmaChoice Canada and our disciplined acquisition strategy," said Alan Simpson, Executive Chair of PharmaCorp, in the statement.

PharmaCorp currently operates three PharmaChoice bannered pharmacies in Canada. The company has established a strategic alliance agreement with PharmaChoice Canada and acquires both PharmaChoice-branded pharmacies and independently owned non-PharmaChoice pharmacies, which it subsequently operates under the PharmaChoice banner.

The vendors in this transaction are at arm’s length to PharmaCorp, meaning they have no prior relationship that would affect the terms of the deal.

PharmaCorp shares are listed on the TSX Venture Exchange under the symbol PCRX. According to InvestingPro analysis, the company appears undervalued based on its Fair Value calculation, with analysts expecting profitability this year despite current losses. Get detailed insights and 8 additional ProTips for PCRX with an InvestingPro subscription.

In other recent news, Pacira BioSciences reported its Q1 2025 earnings, revealing a revenue shortfall of $164.9 million, falling below the expected $175.6 million. This revenue miss was primarily due to declining sales of ZILRETTA, which decreased to $23.3 million from $25.8 million in 2024, despite an increase in sales of EXPAREL to $136.5 million. The company maintains a strong non-GAAP gross margin of 81% and continues to focus on strategic initiatives like the "No Pain" program. Additionally, Pacira BioSciences announced promising clinical data for its gene therapy candidate, PCRX-201, for knee osteoarthritis, which retains its effectiveness despite the presence of anti-Ad5 neutralizing antibodies. The therapy, which uses Pacira’s proprietary adenovirus vector platform, showed significant improvement in patients’ pain, stiffness, and function. Pacira’s CEO expressed optimism about PCRX-201’s potential to provide long-lasting pain relief, and a phase 2 study is underway. Meanwhile, Truist Securities anticipates limited impact on generic drug companies like Pacira BioSciences from a forthcoming White House executive order on drug pricing, which is expected to focus on branded drugs.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.